Answers are grounded in this paper and cite their sources.
Monoclonal antibodies (mAbs) represent one of the largest and fastest-growing classes of biotherapeutics. However, what remains underappreciated is the N-linked glycan on the Fc, a heterogeneous post-translational modification that affects stability, safety, and efficacy. Despite this, glycosylation is still treated as a late-stage critical quality attribute (CQA), characterized and constrained only after a cell line and process are already locked in. I argue that glycosylation should instead be treated as a design variable that enables therapeutic differentiation, a concept framed throughout this perspective as a “mAb glyco-better.” This perspective examines two disciplines central to that shift: Cell line glyco-engineering, which has enabled the directed enrichment of desired glycoform output, and process analytical technology (PAT), which enables near-real-time monitoring of glycosylation. What has not been achieved is their integration. Cell line engineering enables an enriched glycan profile, but a control strategy based on PAT monitoring enables its robust production. Integrating these two technologies will enable next-generation mAbs with enhanced therapeutic functionality by incorporating glycosylation as an intrinsic design parameter.
No takes yet. Share an insight, caveat, or question.
Aron Gyorgypal (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: